- Home
- KF vs SKYE Comparison
KF vs SKYE Comparison
Compare KF & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- SKYE
- Stock Information
- Founded
- KF 1984
- SKYE 2012
- Country
- KF United States
- SKYE United States
- Employees
- KF N/A
- SKYE N/A
- Industry
- KF Investment Managers
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- SKYE Health Care
- Exchange
- KF Nasdaq
- SKYE Nasdaq
- Market Cap
- KF 90.9M
- SKYE 73.4M
- IPO Year
- KF N/A
- SKYE N/A
- Fundamental
- Price
- KF $25.91
- SKYE $2.16
- Analyst Decision
- KF
- SKYE Buy
- Analyst Count
- KF 0
- SKYE 6
- Target Price
- KF N/A
- SKYE $16.60
- AVG Volume (30 Days)
- KF 18.4K
- SKYE 229.4K
- Earning Date
- KF 01-01-0001
- SKYE 08-08-2025
- Dividend Yield
- KF N/A
- SKYE N/A
- EPS Growth
- KF N/A
- SKYE N/A
- EPS
- KF N/A
- SKYE N/A
- Revenue
- KF N/A
- SKYE N/A
- Revenue This Year
- KF N/A
- SKYE N/A
- Revenue Next Year
- KF N/A
- SKYE N/A
- P/E Ratio
- KF N/A
- SKYE N/A
- Revenue Growth
- KF N/A
- SKYE N/A
- 52 Week Low
- KF $18.30
- SKYE $1.14
- 52 Week High
- KF $25.56
- SKYE $9.73
- Technical
- Relative Strength Index (RSI)
- KF 72.61
- SKYE 51.61
- Support Level
- KF $24.74
- SKYE $2.12
- Resistance Level
- KF $25.76
- SKYE $2.22
- Average True Range (ATR)
- KF 0.35
- SKYE 0.19
- MACD
- KF 0.06
- SKYE -0.02
- Stochastic Oscillator
- KF 100.00
- SKYE 34.69
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.